Literature DB >> 14730659

CC chemokine concentrations increase in respiratory distress syndrome and correlate with development of bronchopulmonary dysplasia.

R John Baier1, Abdul Majid, Haroon Parupia, John Loggins, Thomas E Kruger.   

Abstract

Inflammation is one of the primary processes underlying respiratory distress syndrome (RDS) and its evolution into bronchopulmonary dysplasia (BPD). Recruitment and subsequent activation of macrophages in the lung are mediated by CC chemokines. The role of CC chemokines has not been extensively studied in the course of RDS. Serial tracheal aspirates (TA) were obtained from 56 mechanically ventilated infants with birth weights less than 1,500 g during intervals in the first 21 days of life. Tracheal aspirate concentrations of monocyte chemoattractant proteins-1,2,3 (MCP-1,2,3) and macrophage inflammatory proteins-1alpha and -1beta (MIP-1alpha, MIP-1beta) were determined by enzyme-linked immunosorbent assay (ELISA). Tracheal aspirate concentrations of MCP-1, MCP-2, MCP-3, and MIP-1beta increased during the first week of life in infants with RDS, whereas MIP-1alpha concentrations did not increase appreciably. Increased TA cytokine concentrations were associated with the development of BPD. Maximal TA concentrations of MCP-1, MCP-2, MCP-3, MIP-1alpha, and MIP-1beta were significantly higher in infants who were oxygen-dependent at 28 postnatal days compared to infant who were not. Similarly, maximal TA MCP-1, MCP-2, and MCP-3 but not MIP-1alpha and MIP-1beta concentrations were significantly higher in infants who were oxygen-dependent at 36 weeks of postconceptional age (PCA) than those who were not oxygen-dependent at 36 weeks PCA. Histologic chorioamnionitis and isolation of Ureaplasma urealyticum from the airways were associated with higher maximal TA concentrations of MIP-1alpha and MIP-1beta. Pulmonary hemorrhage was associated with increased maximal concentrations of MCP-1, MCP-2, and MCP-3. These data suggest a role for CC chemokines in the development of BPD in the newborn infant. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730659     DOI: 10.1002/ppul.10417

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  34 in total

Review 1.  Pathogenesis and treatment of bronchopulmonary dysplasia.

Authors:  Jason Gien; John P Kinsella
Journal:  Curr Opin Pediatr       Date:  2011-06       Impact factor: 2.856

Review 2.  Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia.

Authors:  Rita M Ryan; Qadeer Ahmed; Satyan Lakshminrusimha
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

3.  Hyperoxia-derived lung damage in preterm infants.

Authors:  Vineet Bhandari
Journal:  Semin Fetal Neonatal Med       Date:  2010-04-28       Impact factor: 3.926

Review 4.  Prevention and management of bronchopulmonary dysplasia: Lessons learned from the neonatal research network.

Authors:  Kathleen A Kennedy; C Michael Cotten; Kristi L Watterberg; Waldemar A Carlo
Journal:  Semin Perinatol       Date:  2016-10       Impact factor: 3.300

5.  Umbilical cord serum interleukin-6, C-reactive protein, and myeloperoxidase concentrations at birth and association with neonatal morbidities and long-term neurodevelopmental outcomes.

Authors:  Yoram Sorokin; Roberto Romero; Lisa Mele; Jay D Iams; Alan M Peaceman; Kenneth J Leveno; Margaret Harper; Steve N Caritis; Brian M Mercer; John M Thorp; Mary Jo O'Sullivan; Susan M Ramin; Marshall W Carpenter; Dwight J Rouse; Baha Sibai
Journal:  Am J Perinatol       Date:  2013-12-11       Impact factor: 1.862

6.  IL-1beta disrupts postnatal lung morphogenesis in the mouse.

Authors:  Kristina Bry; Jeffrey A Whitsett; Urpo Lappalainen
Journal:  Am J Respir Cell Mol Biol       Date:  2006-08-03       Impact factor: 6.914

Review 7.  Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?

Authors:  Clyde J Wright; Haresh Kirpalani
Journal:  Pediatrics       Date:  2011-06-06       Impact factor: 7.124

8.  Cyclooxygenase-2 in newborn hyperoxic lung injury.

Authors:  Rodney D Britt; Markus Velten; Trent E Tipple; Leif D Nelin; Lynette K Rogers
Journal:  Free Radic Biol Med       Date:  2013-04-25       Impact factor: 7.376

9.  Inhibitors of inflammation and endogenous surfactant pool size as modulators of lung injury with initiation of ventilation in preterm sheep.

Authors:  Noah H Hillman; Suhas G Kallapur; J Jane Pillow; Ilias Nitsos; Graeme R Polglase; Machiko Ikegami; Alan H Jobe
Journal:  Respir Res       Date:  2010-10-29

10.  beta6 Integrin subunit deficiency alleviates lung injury in a mouse model of bronchopulmonary dysplasia.

Authors:  Anna Hogmalm; Dean Sheppard; Urpo Lappalainen; Kristina Bry
Journal:  Am J Respir Cell Mol Biol       Date:  2009-08-28       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.